Insight

Enhancing post – operative treatment for pancreatic ductal adenocarcinoma through AI

Photo taken from newstoday.com

Sep 1, 2024, 08:12

Enhancing post – operative treatment for pancreatic ductal adenocarcinoma through AI

Nelson Dusetti posted on X:

“We are very grateful to Davide Melisi for the thoughtful editorial and to Annals of Oncology for featuring our work.

Circumventing human limits in precision oncology: AI-enhanced tailoring of post-operative treatment for pancreatic ductal adenocarcinoma.”

Source: Nelson Dusetti/X

Authors: S. Casalino, C. Zecchetto, V. Merz, A. Quinzii, S. Pietrobono, and D. Melisi.

pancreatic ductal adenocarcinoma

Nelson Dusetti is the Scientific Director of the company Predicting Med (CSO) and Chair of TRANSLATE-IT CRCM. He is also research director at INSERM. He is the Head of the Department of Translational Research and Innovative Therapies at CRCM.

A. Quinzii AI Annals of Oncology C. Zecchetto cancer D. Melisi Davide Melisi Inserm Nelson Dusetti. OncoDaily Oncology pancreatic ductal adenocarcinoma Precision Oncology S. Casalino S. Pietrobono V. Merz

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage